Literature DB >> 17982055

CD8 T cell help for innate antitumor immunity.

Anil Shanker1, Grégory Verdeil, Michel Buferne, Else-Marit Inderberg-Suso, Denis Puthier, Florence Joly, Catherine Nguyen, Lee Leserman, Nathalie Auphan-Anezin, Anne-Marie Schmitt-Verhulst.   

Abstract

Innate immunity is considered to initiate adaptive antitumor responses. We demonstrate that monoclonal CD8 T lymphocytes reactive to tumor Ag P1A on P815 mastocytoma cells provide essential "help" to NK cells for rejection of P1A-deficient tumors. RAG-deficient mice have normal NK cells but do not reject either tumor. Reconstitution of these mice with P1A-specific T cells conferred resistance to both P1A-expressing and -deficient tumor cells provided they were present at the same site. Elimination of Ag-negative tumor variants required both activated T and NK cells. Gene expression profiling of NK cells infiltrating P1A-positive tumors in mice with specific CD8 T cells demonstrated an activated effector phenotype. However, CD8 T cell help to NK cells appeared ineffective for P1A-negative variants separated from the P1A-positive tumor. Local tumor Ag-specific T cell-NK cell collaboration results in the elimination of tumor cells whether they express or not the T cell tumor Ag epitope, thus containing the emergence of tumor escape variants before metastasis.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17982055     DOI: 10.4049/jimmunol.179.10.6651

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  38 in total

1.  CD4(+) T cells contribute to the remodeling of the microenvironment required for sustained tumor regression upon oncogene inactivation.

Authors:  Kavya Rakhra; Pavan Bachireddy; Tahera Zabuawala; Robert Zeiser; Liwen Xu; Andrew Kopelman; Alice C Fan; Qiwei Yang; Lior Braunstein; Erika Crosby; Sandra Ryeom; Dean W Felsher
Journal:  Cancer Cell       Date:  2010-10-28       Impact factor: 31.743

2.  The tumor necrosis factor alpha-induced protein 3 (TNFAIP3, A20) imposes a brake on antitumor activity of CD8 T cells.

Authors:  Marilyn Giordano; Romain Roncagalli; Pierre Bourdely; Lionel Chasson; Michel Buferne; Sho Yamasaki; Rudi Beyaert; Geert van Loo; Nathalie Auphan-Anezin; Anne-Marie Schmitt-Verhulst; Grégory Verdeil
Journal:  Proc Natl Acad Sci U S A       Date:  2014-07-14       Impact factor: 11.205

Review 3.  Adaptive control of innate immunity.

Authors:  Anil Shanker
Journal:  Immunol Lett       Date:  2010-04-13       Impact factor: 3.685

4.  Unleashing antitumor T-cell activation without ensuing autoimmunity: the case for A20-deletion in adoptive CD8+ T-cell therapy.

Authors:  Grégory Verdeil; Anne-Marie Schmitt-Verhulst
Journal:  Oncoimmunology       Date:  2014-12-15       Impact factor: 8.110

Review 5.  Cooperativity of adaptive and innate immunity: implications for cancer therapy.

Authors:  Anil Shanker; Francesco M Marincola
Journal:  Cancer Immunol Immunother       Date:  2011-06-09       Impact factor: 6.968

Review 6.  Perioperative propofol-paravertebral anesthesia decreases the metastasis and progression of breast cancer.

Authors:  Xiu Chen; Peng Lu; Lin Chen; Su-jin Yang; Hong-Yu Shen; Dan-dan Yu; Xiao-hui Zhang; Shan-liang Zhong; Jian-hua Zhao; Jin-hai Tang
Journal:  Tumour Biol       Date:  2015-09-17

7.  Cooperative action of CD8 T lymphocytes and natural killer cells controls tumour growth under conditions of restricted T-cell receptor diversity.

Authors:  Anil Shanker; Michel Buferne; Anne-Marie Schmitt-Verhulst
Journal:  Immunology       Date:  2010-01       Impact factor: 7.397

Review 8.  The immunologic aspects of poxvirus oncolytic therapy.

Authors:  Andrea Worschech; D Haddad; D F Stroncek; E Wang; Francesco M Marincola; Aladar A Szalay
Journal:  Cancer Immunol Immunother       Date:  2009-03-06       Impact factor: 6.968

9.  Emerging concepts in biomarker discovery; the US-Japan Workshop on Immunological Molecular Markers in Oncology.

Authors:  Hideaki Tahara; Marimo Sato; Magdalena Thurin; Ena Wang; Lisa H Butterfield; Mary L Disis; Bernard A Fox; Peter P Lee; Samir N Khleif; Jon M Wigginton; Stefan Ambs; Yasunori Akutsu; Damien Chaussabel; Yuichiro Doki; Oleg Eremin; Wolf Hervé Fridman; Yoshihiko Hirohashi; Kohzoh Imai; James Jacobson; Masahisa Jinushi; Akira Kanamoto; Mohammed Kashani-Sabet; Kazunori Kato; Yutaka Kawakami; John M Kirkwood; Thomas O Kleen; Paul V Lehmann; Lance Liotta; Michael T Lotze; Michele Maio; Anatoli Malyguine; Giuseppe Masucci; Hisahiro Matsubara; Shawmarie Mayrand-Chung; Kiminori Nakamura; Hiroyoshi Nishikawa; A Karolina Palucka; Emanuel F Petricoin; Zoltan Pos; Antoni Ribas; Licia Rivoltini; Noriyuki Sato; Hiroshi Shiku; Craig L Slingluff; Howard Streicher; David F Stroncek; Hiroya Takeuchi; Minoru Toyota; Hisashi Wada; Xifeng Wu; Julia Wulfkuhle; Tomonori Yaguchi; Benjamin Zeskind; Yingdong Zhao; Mai-Britt Zocca; Francesco M Marincola
Journal:  J Transl Med       Date:  2009-06-17       Impact factor: 5.531

10.  Systemic treatment of xenografts with vaccinia virus GLV-1h68 reveals the immunologic facet of oncolytic therapy.

Authors:  Andrea Worschech; Nanhai Chen; Yong A Yu; Qian Zhang; Zoltan Pos; Stephanie Weibel; Viktoria Raab; Marianna Sabatino; Alessandro Monaco; Hui Liu; Vladia Monsurró; R Mark Buller; David F Stroncek; Ena Wang; Aladar A Szalay; Francesco M Marincola
Journal:  BMC Genomics       Date:  2009-07-07       Impact factor: 3.969

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.